Interestingly, data from patients with melanoma, kidney cancer, and lung cancer who receive immune checkpoint inhibitors (ICIs), including programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte–associated protein 4 (CTLA4) checkpoint inhibitors, show that those with obesity or overweight have a better overall and progression-free survival than those without obesity [6,7,8]. This evidence concerns the gene PDCD1 and kidney cancer.